NCT03601923 2026-03-25
Niraparib in Patients With Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
12 trialsNCT05442749 2026-02-17
PARPi-PANC
Centre Leon Berard
Phase 2 Terminated
NCT04673448 2026-01-09
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 1 Active not recruiting
NCT03983993 2026-01-05
NIPAVect
Emory University
Phase 2 Active not recruiting
NCT04779151 2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT03404960 2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2 Completed
NCT06747845 2025-09-16
ParpVax2
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT04409002 2025-08-15
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT04493060 2025-08-07
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Completed
NCT04926324 2025-06-29
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
University of Iowa
Phase 1/2 Terminated
NCT05615818 2025-04-23
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting